<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutation of the KRAS gene in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>(mCRC)has been established as a predictive marker of poor response to anti-EGFR cetuximab </plain></SENT>
<SENT sid="1" pm="."><plain>The Japanese Society of Medical <z:hpo ids='HP_0002664'>Oncology</z:hpo> recommends that the KRAS mutation status at codon 12 and codon 13 should be genotyped by direct-sequencing or allele-specific PCR </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we tested the point mutation of codon 12 and 13 in the KRAS gene by Luminex(xMAP)flow cytometry with sequence-specific oligonucleotide probes for 39 out of 64 unresectable mCRC patients enrolled from Sep 2008 to Oct 2009, who were administered cetuximab in combination with irinotecan(<z:chebi fb="9" ids="27656">CPT</z:chebi>-11)as third-line therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We retrospectively analyzed the relationship between KRAS mutation status and responses to combination therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations in the KRAS gene were detected in 38 </plain></SENT>
<SENT sid="5" pm="."><plain>5% of cases(codon12: 73%, codon 13: 27%), and the median follow-up time was 8 </plain></SENT>
<SENT sid="6" pm="."><plain>2 months(range, 1 </plain></SENT>
<SENT sid="7" pm="."><plain>4-15 </plain></SENT>
<SENT sid="8" pm="."><plain>2 months) </plain></SENT>
<SENT sid="9" pm="."><plain>The response rates for patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> and patients with KRAS mutations were 33 </plain></SENT>
<SENT sid="10" pm="."><plain>3%(95%CI 14 </plain></SENT>
<SENT sid="11" pm="."><plain>5-52 </plain></SENT>
<SENT sid="12" pm="."><plain>2%)and 0%(p=0 </plain></SENT>
<SENT sid="13" pm="."><plain>015); the disease control rates were 75%(95%CI 57 </plain></SENT>
<SENT sid="14" pm="."><plain>7-92 </plain></SENT>
<SENT sid="15" pm="."><plain>3%)and 40%(95%CI, 15 </plain></SENT>
<SENT sid="16" pm="."><plain>2-64 </plain></SENT>
<SENT sid="17" pm="."><plain>8%; p=0 </plain></SENT>
<SENT sid="18" pm="."><plain>044); the median <z:chebi fb="6" ids="52444">TTF</z:chebi> was 7 months(95%CI 4 </plain></SENT>
<SENT sid="19" pm="."><plain>6-9 </plain></SENT>
<SENT sid="20" pm="."><plain>3)and 2 </plain></SENT>
<SENT sid="21" pm="."><plain>3 months(95%CI 1 </plain></SENT>
<SENT sid="22" pm="."><plain>3-3 </plain></SENT>
<SENT sid="23" pm="."><plain>2; p=0 </plain></SENT>
<SENT sid="24" pm="."><plain>0007), and the median OS was 12 </plain></SENT>
<SENT sid="25" pm="."><plain>9 months(95%CI 6 </plain></SENT>
<SENT sid="26" pm="."><plain>7-19 </plain></SENT>
<SENT sid="27" pm="."><plain>1)and 10 </plain></SENT>
<SENT sid="28" pm="."><plain>8 months(95%CI 5 </plain></SENT>
<SENT sid="29" pm="."><plain>0-16 </plain></SENT>
<SENT sid="30" pm="."><plain>7; p=0 </plain></SENT>
<SENT sid="31" pm="."><plain>15), respectively </plain></SENT>
<SENT sid="32" pm="."><plain>Therefore, we concluded that the KRAS mutation in mCRC is a predictive factor for the lack of response to combination therapy with cetuximab plus <z:chebi fb="9" ids="27656">CPT</z:chebi>- 11, as reported in previous clinical studies </plain></SENT>
</text></document>